

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

---

TAKEDA PHARMACEUTICAL  
COMPANY LIMITED et al.,

Plaintiffs,

v.

NORWICH PHARMACEUTICALS, INC.  
et al.,

Defendants.

---

**Civil Action No. 20-8966 (SRC)**

**OPINION & ORDER**

**CHESLER, District Judge**

This matter comes before the Court on the motion *in limine* by Plaintiffs Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. (collectively, “Takeda”) seeking to preclude Defendant Norwich Pharmaceuticals, Inc. (“Norwich”) from offering argument or evidence at trial regarding its strategy in this litigation. For the reasons that follow, the motion will be denied without prejudice.

As Norwich argues in opposition, Takeda has not explained how the material it seeks to exclude is relevant to the issues to be tried, patent infringement and invalidity. Because of this, the motion will be denied, but without prejudice: should the issue arise at trial, Takeda is free to renew the motion.

For these reasons,

**IT IS** on this 24th day of October, 2022

**ORDERED** that Plaintiff's motion *in limine* # 1 (Docket Entry No. 401) is **DENIED** without prejudice.

s/ Stanley R. Chesler  
STANLEY R. CHESLER  
United States District Judge